Fluidigm Opens $40 Million Biochip Plant in Singapore

Fluidigm, a South San Francisco, Calif.-based microfluidics company, opened a $40 million manufacturing and R&D facility in Singapore this week, according to a company statement.

According to Fluidigm, the Singapore facility will assume full manufacturing by mid-2006 for its integrated fluidic circuit chips that are used in protein analysis. The first product to be shipped from the 15,000-square-foot facility will be the Topaz Screening Chip for protein crystallization, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.